Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

As giant companies, especially in technology, propel the S&P 500 to new heights, a select group of mid-sized companies are ...

But if X owner Elon Musk doesn’t see the value in the name, a startup called Operation Bluebird apparently does. The company ...

On this episode of Understanding IP Matters, Allison Gaul discusses the aggressive landscape of data acquisition by various AI entities.

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will ...

Cuts to federally funded research and patents will keep lifesaving products away from the public and cost jobs and revenue.

Sometimes we take things we have around for granted. Basically, we assume that this one useful thing we always have available will be like this whenever we travel around the world. And then we learn ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to ...

Deciding to abandon one of the world’s best-known brands was one of a number of imaginative decisions made by Elon Musk when he purchased Twitter and renamed it X. Now a startup wants to revive the ...

Susan Clayton, creator of WhitePaws RunMitts, still can’t believe her patented mittens are coming to Walmart stores by the ...